Paranoid Schizophrenia in A 31 Years Old Male: A Case Report

Authors

  • Diva Shaffa Aisyah Universitas Lampung
  • High Boy Karmulrubog Hutasoit Rumah Sakit Jiwa Daerah Provinsi Lampung

DOI:

https://doi.org/10.53089/medula.v17i1.1984

Keywords:

Paranoid schizophrenia, persecutory delusion, antipsychotic, psychoeducation

Abstract

Paranoid schizophrenia is a subtype of schizophrenia based on PPDGJ-III classification, characterized by prominent delusions and/or hallucinations, with relatively unobtrusive affective and catatonic symptoms. This condition is often accompanied by medication non-adherence due to poor insight, which contributes to symptom exacerbation and increased risk of rehospitalization. We report a case of a 31-year-old male who presented with agitation, property destruction, and physical assault toward his mother for two days prior to admission. Symptoms first appeared five years earlier, coinciding with the death of his father, presumed to have acted as a significant psychosocial stressor. Mental status examination revealed prominent persecutory delusions alongside grade 1 insight. The patient had a history of medication refusal due to unawareness of his illness and perceived lack of need for treatment. Diagnosis of paranoid schizophrenia (F20.0) was established based on PPDGJ-III criteria. Treatment with risperidone 2x3 mg, trihexyphenidyl 2x2 mg, and valproic acid 2x250 mg alongside psychoeducation for the patient and family resulted in significant clinical improvement during hospitalization. Medication non-adherence due to poor insight was the primary factor worsening the disease course, highlighting the importance of family psychoeducation and medication supervision in long-term management.

Author Biography

Diva Shaffa Aisyah, Universitas Lampung

 

 

References

Zhan Z, Wang J, Shen T. Results of the Global Burden of Disease study for schizophrenia: trends from 1990 to 2021 and projections to 2050. Front Psychiatry. 2025;16:1629032.

Kementerian Kesehatan RI. Laporan Riskesdas 2018 Nasional. Jakarta: Lembaga Penerbit Balitbangkes; 2018.

Badan Kebijakan Pembangunan Kesehatan, Kementerian Kesehatan RI. Survei Kesehatan Indonesia (SKI) 2023 Dalam Angka. Jakarta: Kemenkes RI; 2024. hlm. 144.

Maslim R. Buku Saku Diagnosis Gangguan Jiwa PPDGJ-III. Jakarta: Ilmu Kedokteran Jiwa FK Unika Atma Jaya; 2013.

Freeman D. Understanding and Treating Persecutory Delusions. Schizophrenia Bulletin. 2024;50(2):233–235.

Bighelli I, et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2021;8(11):969–980.

Stambouli M, et al. Violence victimization and perpetration within the caregiver-patient relationship in schizophrenia. PMC. 2023.

Mohammed F, et al. Antipsychotic medication non-adherence and factors associated among patients with schizophrenia in eastern Ethiopia. BMC Psychiatry. 2024;24:108.

Hany M, Rizvi A. Schizophrenia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

Bhattacharyya S, Schoeler T, Di Forti M, Murray R, Cullen AE, Colizzi M. Stressful life events and relapse of psychosis: analysis of causal association in a 2-year prospective observational cohort of individuals with first-episode psychosis in the UK. Lancet Psychiatry. 2023;10(6):414–425.

American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. Washington DC: American Psychiatric Publishing; 2021.

Mellouli A, Charfi N, Gassara I, et al. Risk assessment of aggressive behavior in schizophrenia and schizoaffective disorder: a cross-sectional study. Eur Psychiatry. 2023;66(S1):S1047–S1048.

Yu M, Tan Q, Wang Y, Xu Y, Wang T, Liu D, et al. Correlation between duration of untreated psychosis and long-term prognosis in chronic schizophrenia. Front Psychiatry. 2023;14:1112657.

Salazar de Pablo G, Aymerich C, Guinart D, et al. What is the duration of untreated psychosis worldwide? A meta-analysis of pooled mean and median time and regional trends and other correlates across 369 studies. Psychol Med. 2024;54(4):652–662.

Rose B, Harvey PD. Anosognosia in schizophrenia. CNS Spectrums. 2025;30(1):e24.

Laabidi S, Abidi O, Aissa A, Hosni R, Ouali U, Jomli R. Treatment adherence and insight in schizophrenia spectrum disorders. European Psychiatry. 2024.

Rami A, Sana E, Mejda C, Rahma D. Impact of insight quality on treatment adherence in schizophrenia. European Psychiatry. 2023.

Hany M, Rizvi A. Risperidone. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

Messer T, Bernardo M, Anta L, Martínez-González J. Risperidone ISM: review and update of its usefulness in all phases of schizophrenia. Therapeutic Advances in Psychopharmacology. 2024.

Liang S, et al. Effect of CYP2C19 polymorphisms on serum valproic acid level in Chinese Han patients with schizophrenia. PMC. 2021.

Barlati S, Nibbio G, Vita A. Evidence-based psychosocial interventions in schizophrenia: a critical review. Curr Opin Psychiatry. 2024;37(3):131–139.

Catalan A, et al. Short vs Long DUP in First-Episode Psychosis. Schizophrenia Bulletin. 2025;51(5):1206–1230.

Published

2026-06-30

How to Cite

Aisyah, D. S., & Hutasoit, H. B. K. (2026). Paranoid Schizophrenia in A 31 Years Old Male: A Case Report. Medical Profession Journal of Lampung, 17(1), 144-151. https://doi.org/10.53089/medula.v17i1.1984

Issue

Section

Artikel

Most read articles by the same author(s)